<DOC>
	<DOCNO>NCT01667419</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study evaluate efficacy safety vemurafenib participant completely resect , cutaneous BRAF mutation-positive melanoma high risk recurrence . Participants randomize receive oral dos vemurafenib 960 milligram ( mg ) twice daily match placebo . The anticipated time study treatment 52 week .</brief_summary>
	<brief_title>BRIM8 : A Study Vemurafenib Adjuvant Therapy Patients With Resected Cutaneous BRAF Mutant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm melanoma cutaneous origin Surgically render free disease within 90 day randomization Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 5 year Fully recover effect major surgery significant traumatic injury prior first dose study treatment Adequate hematologic , hepatic , renal function History systemic local therapy ( e.g. , chemotherapy , biologic target therapy , hormonal therapy , photodynamic therapy ) treatment prevention melanoma , include interferon alpha2b pegylated interferon alpha2b History limb perfusion therapy History radiotherapy treatment melanoma Invasive malignancy melanoma time enrollment within 5 year prior first dose study treatment Family history inherit colon cancer syndromes History clinically significant cardiac pulmonary dysfunction Major surgical procedure within 4 week prior first dose study treatment Infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>